By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Morphotek said today that it has entered into two agreements with Fox Chase Cancer Center to acquire clinical samples that it will use to develop companion diagnostic assays for use with drugs currently under development at Morphotek.

Morphotek, a subsidiary of Eisai, said it will fund prospective and archival sample collection programs at Fox Chase to obtain samples from patients who are newly diagnosed with cancer or are being treated for a variety of tumor types.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.